US Supreme Court justices didn’t show all their cards Wednesday during an argument that could influence how legally ...

The justices are set to hear Hikma v. Amarin, a battle over drug patents that could raise costs for patients and change the ...

Mar 9, 2026 Brief amicus curiae of Licensing Executives Society (USA and Canada), Inc. in support of neither party filed. Mar 9, 2026 Brief amici curiae of Patent Law Professors Paul R. Gugliuzza and ...

The U.S. Supreme Court has decided to hear a case between Amarin Pharma and generic drug maker Hikma that puts so-called “skinny labels” back in the spotlight. The high court has agreed to make the ...

Margin outlook for injectables unit lowered Overall 2025 forecasts maintained, including tariff impact First-half profit dips, but not as bad as analyst expectations Aug 7 (Reuters) - Hikma (HIK.L), ...

The sponsor of a new drug application (NDA) is required to list patents that claim the active ingredient, drug product, and approved methods of use for its product in the Orange Book. 21 USC 355(b)(1) ...

Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ...

Hikma Pharmaceuticals USA will invest $1 billion by 2030 to further expand its U.S. manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines ...

The boss of FTSE 100 giant Hikma Pharmaceuticals will be replaced by the firm’s former top chief after the group’s share price dropped by nearly a quarter this year. Riad Mishlawi has exited his role ...

Hikma Pharmaceuticals was fined $4,400 by the Ohio EPA for hazardous waste violations. The company shipped a mislabeled tote of corrosive cleaning chemical to a facility unauthorized to handle ...